9 research outputs found
Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation
Most sequence variants identified hitherto in genome-wide association studies (GWAS) of atrial fibrillation are common, non-coding variants associated with risk through unknown mechanisms. We performed a meta-analysis of GWAS of atrial fibrillation among 29,502 cases and 767,760 controls from Iceland and the UK Biobank with follow-up in samples from Norway and the US, focusing on low-frequency coding and splice variants aiming to identify causal genes. We observe associations with one missense (OR = 1.20) and one splice-donor variant (OR = 1.50) in RPL3L, the first ribosomal gene implicated in atrial fibrillation to our knowledge. Analysis of 167 RNA samples from the right atrium reveals that the splice-donor variant in RPL3L results in exon skipping. We also observe an association with a missense variant in MYZAP (OR = 1.38), encoding a component of the intercalated discs of cardiomyocytes. Both discoveries emphasize the close relationship between the mechanical and electrical function of the heart
Multi-ancestry GWAS of the electrocardiographic PR interval identifies 202 loci underlying cardiac conduction
The electrocardiographic PR interval reflects atrioventricular
conduction, and is associated with conduction abnormalities, pacemaker
implantation, atrial fibrillation (AF), and cardiovascular mortality.
Here we report a multi-ancestry (N = 293,051) genome-wide association
meta-analysis for the PR interval, discovering 202 loci of which 141
have not previously been reported. Variants at identified loci increase
the percentage of heritability explained, from 33.5% to 62.6%. We
observe enrichment for cardiac muscle developmental/contractile and
cytoskeletal genes, highlighting key regulation processes for
atrioventricular conduction. Additionally, 8 loci not previously
reported harbor genes underlying inherited arrhythmic syndromes and/or
cardiomyopathies suggesting a role for these genes in cardiovascular
pathology in the general population. We show that polygenic
predisposition to PR interval duration is an endophenotype for
cardiovascular disease, including distal conduction disease, AF, and
atrioventricular pre-excitation. These findings advance our
understanding of the polygenic basis of cardiac conduction, and the
genetic relationship between PR interval duration and cardiovascular
disease.
</p
Contributions of risk factors and medical care to cardiovascular mortality trends.
Ischaemic heart disease, stroke, and other cardiovascular diseases (CVDs) lead to 17.5 million deaths worldwide per year. Taking into account population ageing, CVD death rates are decreasing steadily both in regions with reliable trend data and globally. The declines in high-income countries and some Latin American countries have been ongoing for decades without slowing. These positive trends have broadly coincided with, and benefited from, declines in smoking and physiological risk factors, such as blood pressure and serum cholesterol levels. These declines have also coincided with, and benefited from, improvements in medical care, including primary prevention, diagnosis, and treatment of acute CVDs, as well as post-hospital care, especially in the past 40 years. These variables, however, explain neither why the decline began when it did, nor the similarities and differences in the start time and rate of the decline between countries and sexes. In Russia and some other former Soviet countries, changes in volume and patterns of alcohol consumption have caused sharp rises in CVD mortality since the early 1990s. An important challenge in reaching firm conclusions about the drivers of these remarkable international trends is the paucity of time-trend data on CVD incidence, risk factors throughout the life-course, and clinical care